Global Health Push Targets RSV Surveillance

World Health Organization Unveils Strategy to Track Deadly Virus

The World Health Organization (WHO) is intensifying its focus on Respiratory Syncytial Virus (RSV), a common pathogen responsible for millions of hospitalizations and nearly 100,000 child deaths globally each year. A new guidance document aims to bolster worldwide genomic surveillance efforts.

Enhancing Global Data Collection

The initiative, an integral part of the WHO’s Global Genomic Surveillance Strategy for Pathogens with Pandemic and Epidemic Potential (2022–2032), seeks to elevate awareness among policymakers about the critical public health role of RSV genomic monitoring. It also aims to reinforce laboratory and bioinformatics capabilities in member states.

A key objective is to create a robust global evidence base of RSV genetic sequences, specifically addressing information gaps in low- and lower-middle-income countries. This improved understanding is vital for tracking the virus’s evolution and informing public health responses.

Standardizing Practices and Building Capacity

The WHO guidance outlines technical and operational considerations for RSV sequencing and bioinformatics. It supports countries, especially those with fewer resources, in enhancing their capacity to genetically analyze RSV strains. This allows for a better grasp of RSV’s phylogenetic diversity.

By promoting standardized genomic surveillance practices, the program encourages the timely submission of genetic sequence data to publicly accessible platforms, fostering international collaboration and rapid information sharing.

Expert Insights on RSV Monitoring

The program’s rollout featured key experts sharing their knowledge. The session began with an introduction to EPI-WIN (Evidence-to-Policy-Innovation & Communication) by representatives from WHO HQ, setting the stage for the day’s discussions.

Remarks from the Global Influenza Program at WHO highlighted the organization’s commitment and the importance of RSV genomic surveillance. Thomas Williams from the University of Edinburgh, UK, provided insights into the operational aspects of RSV genomic surveillance.

Sebastian Maurer-Stroh of GISAid discussed how RSV genetic sequence data can be leveraged for public health benefits. The discussions concluded with a Q&A session and closing remarks from WHO HQ’s EPI-WIN Science and Knowledge Translation team.

According to the U.S. Centers for Disease Control and Prevention (CDC), RSV is a leading cause of infant hospitalizations, underscoring the global significance of enhanced surveillance efforts (CDC).